Clinical outcome and change of antibody level in cerebral sparganosis mansoni patients after treatment: a multicenter study

doi:10.12140/j.issn.1000-7423.2022.02.011

Abstract

Abstract:

Objective To analyze the clinical outcomes and changes in serum IgG antibody titers against Sparganum mansoni after treatment, for further exploring the indicators in assessing the therapeutic effects for cerebral sparganosis. Methods Cases of cerebral sparganosis patients followed-up on continuous inpatient or outpatient treatment were collected from Jiangxi Provincial Institute of Parasitic Diseases, the First Affiliated Hospital of Nanchang University and Guangdong 999 Brain Hospital during 2013 to 2018. The patients were administrated with praziquantel 50 mg/(kg·d) for 10 days per cource, continuing for three cources at a 60-day interval. The surgical treatment includes craniotomy and CT-guided stereotactic aspiration. Twelve months after the treatment with praziquantel and surgery, the clinical manifestations of patients were followed-up, imaging examination (including brain MRI flat and enhanced scan) rechecked, and the serum IgG titer assayed. Statistical analysis was performed using SPSS 18.0 software. Results Eighty-seven cases of cerebral sparganosis were collected, of which 62 patients received praziquantel treatment (10 patients were treated with praziquantel prior to surgery), and 35 patients underwent surgical therapy. After 12 months of treatment, among the 71 patients with good outcomes, 57.7% (41/71) were asymptomatic, 42.3% (30/71) had clinical symptoms, among them 26.8% (19/71) with seizure, 14.1% (10/71) with paresis, and 1.4% (1/71) with diplopia. Radiography showed that 85.9% (61/71) of active enhanced foci were resolving, while 14.1% (10/71) foci remained, of them 12.7% (9/71) were single small nodular lesions. Serology examination revealed that 64.28% (52/71) cases were negative for IgG against Sparganum mansoni (antibody titer < 1 ∶ 100), 23.80% (12/71) had an antibody titer of 1 ∶ 100, and 11.90% (7/71) had the titer of 1 ∶ 200. After treatment for 12 months, 16 patients were of poor outcomes, showing 1/16 was free of symptom, and 15 had clinical symptoms, of them 12/16 patients with seizure, 3/16 with paresis, while headache, aggravating illness, no significant improvement and emerging new symptoms were found of 1 case each. Radiography indicated that among the cases, 6/16 showed no changes in lesion images, 1/16 had enlarged foci, 7/16 changes in lesion location, and 2/16 newly enhanced lesions. Serology examination on the patients showed 4/16 had an antibody titer of 1 ∶ 400, 8/16 had the titer of 1 ∶ 800 and 4/16 had the titer of 1 ∶ 1 600. Conclusion Most of the cerebral sparganosis cases had a good prognosis after praziquantel and surgery treatment. Serological tests could be used for assessment of recent therapeutic effect in 12 months, redeeming the limitations in appraisal by symptoms and imaging.

Key words: Cerebral sparganosis, Praziquantel, Surgery, Clinical outcome, 12-months short-term efficacy

CLC Number:

R532.31

XIE Hui-qun, XU Yun, GONG Zhi-hong, HU Fei, WAN Hui, XU Chun-hua, WU Jie, LIU Jun-pu, HONG Dao-jun. Clinical outcome and change of antibody level in cerebral sparganosis mansoni patients after treatment: a multicenter study[J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2022, 40(2): 204-210.

Figures/Tables 3

Table 1

Fig. 1

Fig. 2

References 29

[1]	Xu Y,, Wan H,, Hong DJ, et al. Cerebral clinical features and outcome of 123 patients with sparganosis[J]. Jiangxi Med J, 2017, 52(4): 286-289. (in Chinese)
	(徐芸,, 万慧,, 洪道俊, 等. 123例曼氏裂头蚴病的临床特点及治疗观察[J]. 江西医药, 2017, 52(4): 286-289.)
[2]	Yan XQ,, Li XL,, Sun ZQ, et al. Clinical features of 83 cases of cerebral sparganosis[J]. Chin J Parasitol Parasit Dis, 2021, 39(2): 240-245. (in Chinese)
	(闫学强,, 李晓龙,, 孙祯卿, 等. 83例脑裂头蚴病患者临床资料分析[J]. 中国寄生虫学与寄生虫病杂志, 2021, 39(2): 240-245.)
[3]	Kim JG,, Ahn CS,, Sohn WM, et al. Human sparganosis in Korea[J]. J Korean Med Sci, 2018, 33(44): e273. doi: 10.3346/jkms.2018.33.e273
[4]	Lo Presti A,, Aguirre DT, et al. Cerebral sparganosis: case report and review of the European cases[J]. Acta Neurochir (Wien), 2015, 157(8): 1339-1343. doi: 10.1007/s00701-015-2466-9 pmid: 26085111
[5]	Zeng QR,, He M,, Wang F, et al. Pathogen identification of 10 suspected cases of sparganosis mansoni[J]. Chin J Parasitol Parasit Dis, 2012, 30(3): 224-227, 232. (in Chinese)
	(曾庆仁,, 贺美,, 王芳, 等. 10例疑似曼氏裂头蚴病的病原学诊断[J]. 中国寄生虫学与寄生虫病杂志, 2012, 30(3): 224-227, 232.)
[6]	Meng YM,, Kuang ZW,, Liao L, et al. Case report: morphologic and genetic identification of cerebral sparganosis[J]. Am J Trop Med Hyg, 2019, 101(5): 1174-1176. doi: 10.4269/ajtmh.19-0468
[7]	Zhu YL,, Ye LQ,, Ding XS, et al. Cerebral sparganosis presenting with atypical postcontrast magnetic resonance imaging findings: a case report and literature review[J]. BMC Infect Dis, 2019, 19(1): 748. doi: 10.1186/s12879-019-4396-2
[8]	Zhang P,, Zou Y,, Yu FX, et al. Follow-up study of high-dose praziquantel therapy for cerebral sparganosis[J]. PLoS Negl Trop Dis, 2019, 13(1): e0007018. doi: 10.1371/journal.pntd.0007018
[9]	Hong DJ,, Xie HQ,, Wan H, et al. Efficacy comparison between long-term high-dose praziquantel and surgical therapy for cerebral sparganosis: a multicenter retrospective cohort study[J]. PLoS Negl Trop Dis, 2018, 12(10): e0006918. doi: 10.1371/journal.pntd.0006918
[10]	Gonzenbach RR,, Kong Y,, Beck B, et al. High-dose praziquantel therapy for cerebral sparganosis[J]. J Neurol, 2013, 260(5): 1423-1425. doi: 10.1007/s00415-013-6901-7 pmid: 23546305
[11]	Xie HQ,, Long Y,, Xu Y, et al. Clinical features, radiological characteristics and pathological changes in 42 patients with cerebral sparganosis[J]. Chin J Neurol, 2015, 48(2): 108-113. (in Chinese)
	(谢慧群,, 龙勇,, 徐芸, 等. 脑曼氏裂头蚴病患者42例的临床、影像与病理特点分析[J]. 中华神经科杂志, 2015, 48(2): 108-113.)
[12]	Hong DJ,, Xie HQ,, Zhu M, et al. Cerebral sparganosis in mainland Chinese patients[J]. J Clin Neurosci, 2013, 20(11): 1514-1519. doi: 10.1016/j.jocn.2012.12.018
[13]	Chen XH,, Shi GF. Clinical analysis of 6 cases with cerebral sparganosis mansoni[J]. Chin J Parasitol Parasit Dis, 2010, 28(5): 397-398. (in Chinese)
	(陈先汉,, 施光峰. 脑曼氏裂头蚴病6例临床分析[J]. 中国寄生虫学与寄生虫病杂志, 2010, 28(5): 397-398.)
[14]	Ye SK,, Xu L,, Huang Q, et al. The epidemiology, clinical feature, radiology and outcome of 8 cases with cerebral sparganosis mansoni[J]. Chin J Parasitol Parasit Dis, 2018, 36(2): 144-147. (in Chinese)
	(叶善可,, 徐烈,, 黄琴, 等. 8例脑曼氏裂头蚴病的流行病学特点、临床特征、影像学表现与预后分析[J]. 中国寄生虫学与寄生虫病杂志, 2018, 36(2): 144-147.)
[15]	Kim YB,, Hw ang SN,, Cho SY, et al. Cereberal spargnosis: two cases diagnosed by CT/MR and ELISA tests[J]. J Korean Neurosurg Soc, 1993, 22(6): 585-590.
[16]	Choi SH,, Kang SY,, Kong Y, et al. Antigenic protein fractions reacting with sera of sparganosis patients[J]. Kisaengchunghak Chapchi, 1988, 26(3): 163-167.
[17]	Hwang JM,, Hwang DS,, Kang C, et al. Subcutaneous sparganosis mimicking soft tissue tumor: a case report[J]. Int Med Case Rep J, 2019, 12: 47-50.
[18]	National Health and Family Planning Commission. Diagnosis of sparganosis WS 438-2013[S]. Beijing: Standards Press of China, 2013. (in Chinese)
	国家卫生和计划生育委员会. 裂头蚴病的诊断 WS 438-2013[S]. 北京: 中国标准出版社, 2013.
[19]	Wang P,, Su XY,, Mao Q, et al. The surgical removal of a live tapeworm with an interesting pathologic finding most likely representing the migration path: a case report of cerebral sparganosis[J]. Clinics (Sao Paulo), 2012, 67(7): 849-851. doi: 10.6061/clinics/2012(07)24
[20]	Chu SG,, Lu XS,, Wang Y, et al. Magnetic resonance imaging features of pathologically proven cerebral sparganosis[J]. J Int Med Res, 2013, 41(3): 867-877. doi: 10.1177/0300060513480925
[21]	Shirakawa K,, Yamasaki H,, Ito A, et al. Cerebral sparganosis: the wandering lesion[J]. Neurology, 2010, 74(2): 180. doi: 10.1212/WNL.0b013e3181c91a15 pmid: 20065255
[22]	Torres JR,, Noya OO,, Noya BA, et al. Treatment of proliferative sparganosis with mebendazole and praziquantel[J]. Trans R Soc Trop Med Hyg, 1981, 75(6): 846-847. doi: 10.1016/0035-9203(81)90428-4
[23]	Deng L,, Xiong PJ,, Qian SK. Diagnosis and stereotactic aspiration treatment of cerebral sparganosis: summary of 11 cases[J]. J Neurosurg, 2011, 114(5): 1421-1425. doi: 10.3171/2010.4.JNS1079 pmid: 20486898
[24]	Sohn WM,, Hong ST,, Chai JY, et al. Infectivity of the Sparganum treated by praziquantel, gamma-irradiation and mechanical cutting[J]. Korean J Parasitol, 1993, 31(2): 135-139. pmid: 8343455
[25]	Chan JD,, Zarowiecki M,, Marchant JS. Ca²⁺ channels and praziquantel: a view from the free world[J]. Parasitol Int, 2013, 62(6): 619-628. doi: 10.1016/j.parint.2012.12.001
[26]	Andrews P,, Thomas H,, Pohlke R, et al. Praziquantel[J]. Med Res Rev, 1983, 3(2): 147-200. pmid: 6408323
[27]	Gonzenbach RR,, Kong Y,, Beck B, et al. High-dose praziquantel therapy for cerebral sparganosis[J]. J Neurol, 2013, 260(5): 1423-1425. doi: 10.1007/s00415-013-6901-7 pmid: 23546305
[28]	Doenhoff MJ,, Cioli D,, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis[J]. Curr Opin Infect Dis, 2008, 21(6): 659-667. doi: 10.1097/QCO.0b013e328318978f pmid: 18978535
[29]	Kim DG,, Paek SH,, Chang KH, et al. Cerebral sparganosis: clinical manifestations, treatment, and outcome[J]. J Neurosurg, 1996, 85(6): 1066-1071. pmid: 8929496

中心名称 Center	病例数 No. case	治疗例数 No. case
中心名称 Center	病例数 No. case	吡喹酮 Praziquantel	外科 Surgey
江西省寄生虫病防治研究所Jiangxi Provincial Institute of Parasitic Diseases	52 - 6^a	52 - 6^a	0
南昌大学第一附属医院 First Affiliated Hospital of Nanchang University	31	10 - 4^a	21 + 4^a
广东三九脑科医院 Guangdong 999 Brain Hospital	4 + 6^a	0	4 + 6^a
合计Total	87	62 - 10^a	35